AGEX THERAPEUTICS INC has a total of 24 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2013. It filed its patents most often in United States, Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are DAVID GLADSTONE INST, JOSLIN DIABETES CENTER INC and VETERINARMEDIZINISCHE UNI WIEN.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | Australia | 6 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | WIPO (World Intellectual Property Organization) | 4 | |
#5 | Republic of Korea | 2 | |
#6 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Agriculture |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Microorganisms | |
#3 | Analysing materials | |
#4 | Therapeutic chemical compounds | |
#5 | Peptides | |
#6 | Animal care | |
#7 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Sternberg Hal | 9 |
#2 | West Michael | 8 |
#3 | Hantash Basil M | 7 |
#4 | West Michael D | 6 |
#5 | Chapman Karen | 5 |
#6 | Larocca Dana | 3 |
#7 | Lee Jieun | 2 |
#8 | Janus Jeffrey | 2 |
#9 | West Michae D | 1 |
#10 | Bignone Paola A | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021041355A1 | Differentially-methylated regions of the genome useful as markers of embryo-adult transitions | |
US2020306296A1 | Induced tissue regeneration using extracellular vesicles | |
US2020225213A1 | Compositions and methods for detecting cardiotoxicity | |
WO2019209892A1 | Improved methods for inducing tissue regeneration and senolysis in mammalian cells | |
US2019151372A1 | Pericyte cell exosomes | |
KR20200136047A | Hla g-modified cells and methods |